list of publications

selected

Bhattacharya, N., Sarno, A., Idler, I., Fuehrer, M., Zenz, T., Doehner, H., Stilgenbauer, S., Mertens, D. "High throughput detection of NFkB activity using a sensitive oligo-based chemiluminescent ELISA", International Journal of Cancer, in press, IF 4,734

Zenz, T., Mertens, D., Kueppers, R., Doehner, H., Stilgenbauer, S. "From pathogenesis to treatment of chronic lymphocytic leukaemia.", Nature Reviews Cancer, in press, IF 30.762 (review article)

Idler, I., Giannopoulos, K., Zenz, T., Bhattacharya, N., Nothing, M., Doehner, H., Stilgenbauer, S., Mertens, D. "Lenalidomide treatment of chronic lymphocytic leukemia patients reduces regulatory T-cells and induces Th17 T-helper cells." British Journal of Haematology, in press, IF 4,478

Mertens, D.
, Philippen, A., Ruppel, M., Allegra, D., Bhattacharya, N., Tschuch, C., Wolf, S., Idler, I., Zenz, T., Stilgenbauer, S. "Chronic Lymphocytic Leukemia and 13q14: miRs and more",  Leukemia & Lymphoma, in press, IF 1,559  (review article)

Tschuch, C., Schulz, A., Pscherer, A., Werft, W., Benner, A., Hotz-Wagenblatt, A., Serra-Barrionuevo, L., Lichter, P., Mertens, D. (2008) "Off-target effects of siRNA specific for GFP", BMC Molecular Biology jun 24;9:60. IF 3,371
 

Mertens, D., S. Wolf, C. Tschuch, C. Mund, D. Kienle, S. Ohl, P. Schroeter, F. Lyko, H. Dohner, S. Stilgenbauer and P. Lichter (2006). "Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism."
Proc Natl Acad Sci U S A 103(20): 7741-6. IF 10.452

Mertens, D., S. Wolf, P. Schroeter, C. Schaffner, H. Dohner, S. Stilgenbauer and P. Lichter (2002). "Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia." Blood 99(11): 4116-21. IF 9.782

Wolf, S., D. Mertens, C. Schaffner, C. Korz, H. Dohner, S. Stilgenbauer and P. Lichter (2001). "B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions." 
Hum Mol Genet 10(12): 1275-85. IF 7.801

comprehensive

Philippen, A., Diener, S., Zenz, T., Doehner, H., Stilgenbauer, S., Mertens, D. "SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)", Brithish Journal of Haematology, in press, IF 4.478

Bhattacharya, N., Sarno, A., Idler, I., Fuehrer, M., Zenz, T., Doehner, H., Stilgenbauer, S., Mertens, D. "High throughput detection of NFkB activity using a sensitive oligo-based chemiluminescent ELISA", International Journal of Cancer, in press, IF 4,734

Zenz, T., Mertens, D., Kueppers, R., Doehner, H., Stilgenbauer, S. "From pathogenesis to treatment of chronic lymphocytic leukaemia.", Nature Reviews Cancer, in press, IF 30.762 (review article)

Idler, I., Giannopoulos, K., Zenz, T., Bhattacharya, N., Nothing, M., Doehner, H., Stilgenbauer, S., Mertens, D. "Lenalidomide treatment of chronic lymphocytic leukemia patients reduces regulatory T-cells and induces Th17 T-helper cells." British Journal of Haematology, in press, IF 4,478

Sandra Loeder, Thorsten Zenz, Andrea Schnaiter, Mertens, D., Dirk Winkler, Hartmut Doehner, Klaus-Michael Debatin, Stephan Stilgenbauer, Simone Fulda (2009):  Small molecule XIAP inhibitors act in concert with TRAIL to overcome apoptosis resistance in chronic lymphocytic leukemia, Cancer Research, in press, IF 7,514

Zenz, T., S. Habe, T. Denzel, J. Mohr, D. Winkler, A. Buhler, A. Sarno, S. Groner, D. Mertens, R. Busch, M. Hallek, H. Dohner and S. Stilgenbauer (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial Blood , in press, IF 9.782 

Zenz, T., Mohr, J., Edelmann, J., Sarno, A., Hoth, P., Heuberger, M., Helfrich, H., Mertens, D., Doehner, H., Stilgenbauer, S. Treatment Resistance in Chronic Lymphocytic leukemia - The role of the P53 Pathway, Leukemia & Lymphoma, in press, IF 1,559 (Review article)

Giannopoulos, K., Buehler, A., Mertens, D., Barth, T., Idler, I., Kroeber, A., Greiner, J., Chocholska, S., Dmoszynska, A., Rolinsky, J., Döhner, H., Stilgenbauer, S., Schmitt, M. The receptor for hyaluronic acid mediated motility (RHAMM): Characterization of an immunotherapeutical target which is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) patients, Leukemia, in press, IF 6.924

Zenz, T, Mohr, J, Eldering, E, Kater, A, van Oers, MHJ, Buehler, A, Kienle, D, Winkler, D, Duerig, J, Mertens, D, Doehner, H, Stilgenbauer, S, (2008) "MiR34a is associated with an impaired DNA damage response and poor prognostic features in CLL", Blood , in press. IF 9.782 

Tschuch, C., Schulz, A., Pscherer, A., Werft, W., Benner, A., Hotz-Wagenblatt, A., Serra-Barrionuevo, L., Lichter, P., Mertens, D. (2008) "Off-target effects of siRNA specific for GFP", BMC Molecular Biology jun 24;9:60. IF 3,371

Thorsten Zenz, Daniel Mertens, Hartmut Doehner, Stephan Stilgenbauer, "Molecular diagnostics in chronic lymphocytic leukemia - Pathogenetic and clinical implications", Leukemia & Lymphoma, 49(5):864-73, (2007) IF 1,559

Claudia Kalla, Markus Scheuermann, Ina Kube, Magdalena Schlotter, Daniel Mertens, Hartmut Doehner, Stephan Stilgenbauer, Peter Lichter "Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukemia: Ecifence for a pathogenic role of NPAT, CUL5 and PPP2R1B", Eur J Cancer 43(8), 1328-35, (2007) IF 3,706 

Ilka Prowatke, Frauke Devens, Axel Benner, Elisabeth F. Gröne , D.Mertens, Hermann-Josef Gröne, Peter Lichter, Stefan Joos, BARK1 and MYC protein expression is associated with prostate cancer progression, Br. J. Cancer, 96(1), 82-8, (2006) IF 4.115

Wolf, S., D. Mertens, A. Pscherer, P. Schroeter, D. Winkler, H. J. Grone, C. Hofele, K. Hemminki, R. Kumar, G. Steineck, H. Dohner, S. Stilgenbauer and P. Lichter (2006). "Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer." Int J Cancer 118(7): 1831-5. IF 4.416

Kienle, D., A. Benner, A. Krober, D. Winkler, D. Mertens, A. Buhler, T. Seiler, U. Jager, P. Lichter, H. Dohner and S. Stilgenbauer (2006). "Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes." Blood 107(5): 2090-3. IF 9.782

Mertens, D., S. Wolf, C. Tschuch, C. Mund, D. Kienle, S. Ohl, P. Schroeter, F. Lyko, H. Dohner, S. Stilgenbauer and P. Lichter (2006). "Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism." Proc Natl Acad Sci U S A 103(20): 7741-6. IF 10.452

Mannherz, O., D. Mertens, M. Hahn and P. Lichter (2006). "Functional screening for proapoptotic genes by reverse transfection cell array technology." Genomics 87(5): 665-72. IF 3.840

Henrich, K. O., M. Fischer, D. Mertens, A. Benner, R. Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J. S. Wei, J. Khan, M. Schwab and F. Westermann (2006). "Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients." Clin Cancer Res 12(1): 131-8. IF 5.623

Adamowicz, M., B. Radlwimmer, R. J. Rieker, D. Mertens, M. Schwarzbach, P. Schraml, A. Benner, P. Lichter, G. Mechtersheimer and S. Joos (2006). "Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas." Genes Chromosomes Cancer 45(9): 829-38. IF 3.937

Kalla, C., H. Nentwich, M. Schlotter, D. Mertens, K. Wildenberger, H. Dohner, S. Stilgenbauer and P. Lichter (2005). "Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes." Genes Chromosomes Cancer 42(2): 128-43. IF 3.937

Kienle, D. L., C. Korz, B. Hosch, A. Benner, D. Mertens, A. Habermann, A. Krober, U. Jager, P. Lichter, H. Dohner and S. Stilgenbauer (2005). "Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes." J Clin Oncol 23(16): 3780-92. IF 11.810

Korz, C., A. Pscherer, A. Benner, D. Mertens, C. Schaffner, E. Leupolt, H. Dohner, S. Stilgenbauer and P. Lichter (2002). "Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes." Blood 99(12): 4554-61. IF 9.782

Mertens, D., S. Wolf, P. Schroeter, C. Schaffner, H. Dohner, S. Stilgenbauer and P. Lichter (2002). "Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia." Blood 99(11): 4116-21. IF 9.782

Wolf, S., D. Mertens, C. Schaffner, C. Korz, H. Dohner, S. Stilgenbauer and P. Lichter (2001). "B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions." Hum Mol Genet 10(12): 1275-85. IF 7.801

Mertens, D., S. Wolf, L. Bullinger, S. Ohl, C. Schaffner, H. Dohner, S. Stilgenbauer and P. Lichter (2000). "BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22- p31, BCMSUN-like." Int J Cancer 88(5): 692-7. IF 4.416

Bullinger, L., E. Leupolt, C. Schaffner, D. Mertens, M. Bentz, P. Lichter, H. Dohner and S. Stilgenbauer (2000). "BCL10 is not the gene inactivated by mutation in the 1p22 deletion region in mantle cell lymphoma." Leukemia 14(8): 1490-2. IF 5.810

Lammer, C., S. Wagerer, R. Saffrich, D. Mertens, W. Ansorge and I. Hoffmann (1998). "The cdc25B phosphatase is essential for the G2/M phase transition in human cells." J Cell Sci 111 ( Pt 16): 2445-53. IF 6.910